GlassScriptPhysician profile
Nilay V Desai
NPI 1336157122
$360,990.62
in general payments reported to CMS, 2019-2025
19 companies · $44K in 2025
The $44K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131K · 2020: $59K · 2021: $41K · 2022: $43K · 2023: $25K · 2024: $18K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Travel and Lodging: $5,636 · Food and Beverage: $1,558 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $80,011.50 |
| Travel and Lodging | $5,635.70 |
| Food and Beverage | $1,557.84 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $171,463.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $102,493.21 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53,571.00 | 2019-2025 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $20,909.13 | 2019-2020 | |
| Abbott Laboratories | $5,598.34 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $5,498.54 | 2021-2023 | |
| Ibsa Pharma INC. | $1,000.00 | 2020-2021 | |
| Amgen INC. | $105.83 | 2019 | |
| Medtronic Minimed, INC. | $91.15 | 2019 | |
| Radius Health, INC. | $58.10 | 2021 | |
| Sanofi-Aventis U.S. LLC | $51.45 | 2021-2023 | |
| Beta Bionics, INC. | $29.26 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Cequr Corporation | $29.23 | 2024-2025 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $20.74 | 2020 | |
| Insulet Corporation | $20.06 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $19.39 | 2020 | |
| Amneal Pharmaceuticals LLC | $17.45 | 2025 | Unithroid |
| Lifescan, INC. | $14.68 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilay Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.